Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
4 buys on Fast Money ..$18 to $20 in 21
Did it have to be done ?
sorry..wrong link..try this one
I Just listened to this..she made mentioned of an uplisting to TSX but no mention of Nasdaq, which I was referring to as my disappointment. Maybe I misunderstood. , but i was under the impression a Nasdaq listing was a priority and that our stock price had to stay above $3 for a period of months (?)
The fruits of her labor would have paid more if she had just waited until the uplisting...and that's is surely a huge disappointment. The timing of her actions could not have come at a more inopportune time as an Uplisting was becoming a hopeful reality. Now what? How long now ? will it even happen now ? How low will the stock price drop ? I was a huge fan of hers and thought she was doing a great job, and was so confident she would lead us to becoming a huge success....but in my opinion , she has just screwed me and all the other hopeful shareholders to the wall.
FREE
Does our ceo's recent trading activity not give you a reason to be concerned ?
Thanks
Can you provide a link ? thanks
You have to draw Dolly a picture.
Thanks..I didn't make 450 % on my FCEL calls..sold way to soon..but did ok..my finger is on the buy button again...hope soon..Good luck to you too.
I hope APHA rocks my world. I have some April $10 calls..do you have an idea what happens to them ?
Thx. Appreciate your response. I hope we never see the 8's again.
what are your thoughts on the gap 8/8.50?
I agree...and it can't happen soon enough.
yeah..let's elect Obama's puppet so O and his crooked gang can keep fundamentally changing America.
Thank you javanader13
will someone list the 4 companies making bids to the uspo?
TIA
nbm16..Thanks for your reply and info. Very interesting..just might buy moreeeeeeeeeeeee
Please tell me about the June 8th announcement with a link ..thanks
guess you called the coronavirus also.
forgot the link :
MarketBeat Daily <newsletters@analystratings.net>
Sat 11/9/2019 2:29 PM
This Week's Most Talked About Upgrades and Downgrades
Aphria (NYSE:APHA) is now covered by analysts at Cantor Fitzgerald on Tuesday. They set an "overweight" rating and a $10.40 price target on the stock. 105.1% upside from the current price of $5.07. This rating was viewed 174 times. Read More.
Has anyone noticed all the Form4
Ske..thanks..
When I click on a message to read, I have to scroll down to the bottom of page to read it..how can I change this ?
I'm skeptical that no matter what kind of deal is made, we, the common shareholders, will somehow get it up the wazoo.
just saying....
I loaded up in the .80's...and holding.
Will the daytraders dump before the close ? hope so,I have a buy in $1.30ish
part 11..
"We are very familiar with ASTM's new CEO, Tim Mayleben, who took over the reins at the Company late last year.
"Mr. Mayleben served as COO of Esperion Therapeutics, where he led the raising of more than $200 million in venture capital and institutional equity funding.
"On top of that, far and away his most impressive achievement was when Tim led the negotiations that triggered the acquisition of Esperion by Pfizer in December 2003 at a huge premium.
"Tim has significant operations experience and has no pie-in-the-sky illusions regarding the difficulty of navigating new technologies through the FDA gauntlet.
"We have found through the years that it is much harder to get new technologies to market than anyone has forecasted.
"This puts an even higher premium on quality management, as the promise of a technology is not enough in the hands of poor leadership.
"The upcoming year is shaping up to be an excellent time for ASTM. The company has recently raised cash that will enable them to start their Phase III progrma for CLI patients in 2011.
"We could also see the CLI Phase II data published in a peer-reviewed medical journal, which would be an important validatation of the Company's technologies and drug dvelopment candidates.
"Interestingly, publication of Phase II data was one of the main drivers that got Esperion bought by Pfizer for a huge premium.
"We have been impressed with ASTM's management team and have growing confidence that they will continue to deliver and create value for their shareholders.
"With the recent financing out of the way we believe the stock is poised to regain momentum. We are recommending ASTM as a buy under $3.50 with a one year target of $7."
Post from the yahoo board...part 1
Top Picks 2011: Aastrom Biosciences (ASTM)
Posted Dec 31st 2010 9:00AM by Steven HalpernSteven Halpern RSS Feed
Filed under: Newsletters, Stocks to Buy, Best Stocks for 2011
Aastrom (ASTM) logoThis post is one in a series in which more than 60 newsletter advisors share their Top Stock Picks for 2011. This special report is courtesy of TheStockAdvisors.com.
"We are recommending Aastrom Biosciences (ASTM) as our top stock recommendation for 2011 because we believe that they are the clear leader in the regenerative stem cell space," notes biotech sector specialist John McCamant.
The editor of The Medical Technology Stock Letter explains, "The company is focused on the development of autologous cellular therapies for the treatment of cardiovascular diseases utilizing its Tissue Repair Cell (TRC) technology.
"We are impressed with the Phase II clinical data sets we have seen in Critical Limb Ischemia (CLI) and ASTM will start a Phase III development program to treat CLI patients in 2011.
"More importantly, we believe that ASTM has the experienced and motivated management team with a proven track record of creating shareholder value.
"Tissue repair cell (TRC) technology is ASTM's platform for processing a patient's bone marrow cells into a therapeutic treatment. The collected sample of bone marrow will contain mostly hematopoietic and endothelial stem cells.
"Simply put, ASTM's technology increases the amounts of other types of cells in a way that mimics the response to a wound, increasing the sample's regenerative properties.
"When the cells are re-inserted into the patient they act in harmony to regenerate the vasculature (in the case of CLI).
"ASTM has published convincing research, corroborated by independent experts, that a mixed population of stem and progenitor cells is optimal for regenerating tissue, and it makes sense intuitively that many cells will work better than a single type since the body naturally uses many different cell types acting in concert.
"In addition to the CLI clinical program, ASTM also has an ongoing program to use the TRC technology to treat dilated cardiomyopaty (DCM).
"DCM is an enlargement of the heart due to weakening, leading to further degradation of cardiac function and associated with end- stage heart failure.
"The only option left for these patients is a heart transplant, but ASTM's technology may help to regenerate the heart and add time and quality to these patient's lives. Both of these clinical programs and ASTM's TRC technology are protected by a strong intellectual property portfolio.
ASTM selling shares ?
but that board is useless.
try ASTMD
ace..what happens when the a/s is maxed out ? has a reverse split or an increase in a/s been discussed ?
I remember this stock running from sub penny to over .20 a few years ago..haven't been watching since, but at these prices, might be worth a gamble.
I say yes too..and for people like me who still are uncomfortable with ESC, ASTM gives us a opportunity to ride the stem cell wave.
I am hoping that the advantages of patients using ASC will be promising enough that it will recieve part of the funding.
I am long on ASTM !
GLTA
dgplexus..
if it's not too personal..may I ask if you are still buying at current price ? thanks
has a r/s been approved ?
lol... i don't know how to short a stock..I am just a novice trader still learning the basics. One thing I do is read alot and I just learned about the contango just a couple of weeks ago. Good for you that you know how this stock trades..
and GLTU.
here is an example..
DXO BUYERS BEWARE 24-Dec-08 06:28 am Exchange-traded products have let individuals easily access commodities and other sectors without opening up a futures account, but investors should make sure to research them thoroughly before jumping in. For example, ETNs have come under pressure recently because they carry credit risk.
Additionally, some of the funds listed above use the futures markets to get exposure to oil and commodities prices. This is important because oil markets are currently in a state known as "contango," in which longer-dated futures are more expensive than the spot price. Heavy contango may at times indicate a market perception of oversupply.
The bottom line is that funds that use futures need to continually "roll" the contracts to maintain exposure. When markets are in contango, the funds lose money on the trade and can see higher losses than what is suggested by following the spot prices. This issue has been a source of confusion in recent years with the proliferation of ETFs and ETNs tracking oil and commodities.
Investors also need to be aware that gains on these products that invest in futures or hold physical commodities can be taxed at a higher rate than funds that invest in stocks. Rating :
(12 Ratings)Rate it: